Navigation Links
Phase 2a Findings Demonstrate that CSL112, A Novel Apolipoprotein A-I Infusion Therapy, Has a Favorable Safety Profile, is Well Tolerated and Increases Cholesterol Efflux Capacity in Stable Atherothrombotic Patients
Date:11/20/2013

DALLAS, Nov. 20, 2013 /PRNewswire/ -- Results of a Phase 2a trial of CSL112, sponsored by CSL Limited, demonstrated favorable safety and tolerability when administered to patients with stable atherothrombotic disease.  The trial data for CSL112 also showed a dramatic and rapid increase in key biomarkers of reverse cholesterol transport, a process by which cholesterol is removed from arteries and transported to the liver for clearance.

"We are encouraged by the positive safety profile observed in the trial which supports progression of the CSL112 clinical development program," said Pierluigi Tricoci, MD, PhD, MHS, Duke Clinical Research Institute, and lead study author. "We know there is a need for novel approaches to reduce the high risk of early recurrent ischemic events after acute coronary syndrome. CSL112 is a promising treatment targeting coronary atherosclerotic plaques causing these events and deserves further investigation."

Three separate analyses of data from the CSL112 Phase 2a study were presented at the American Heart Association 2013 Scientific Sessions. The presentations examined the safety and tolerability, pharmacokinetics and lipid biomarker profile, and potential antiplatelet effects of CSL112 on top of dual antiplatelet therapy.

Study Design and Key Findings
The CSL112 Phase 2a study was a randomized, multicenter, double-blind, placebo-controlled trial (n=44) that evaluated the safety and pharmacokinetics/pharmacodynamics (PK/PD) of a single-dose administration of CSL112 in patients with stable atherothrombotic disease. Patients were randomized to a single infusion of either CSL112 at 1.7, 3.4 or 6.8g doses or masked placebo. PK and PD were assessed up to 7 days after the infusion during the active treatment period. Safety was assessed for up to 90 days after the infusion.            
'/>"/>

SOURCE CSL Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Topokine Commences Phase 2 Clinical Trial of XAF5 Gel to Reduce Submental Fat
2. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
3. Surprise: Viruses Can Cause Disease during Latent Phase; New Evidence Supports Microcompetition Theory
4. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
5. Omeros to Present Data from OMS302 Phase 3 Clinical Program at the American Academy of Ophthalmology Annual Meeting
6. GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
7. Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
8. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
9. KemPharm Completes Successful End-of-Phase 2 Meeting with FDA
10. Polaris Group Announces Positive Results for Phase 2 Study of ADI-PEG 20 in Malignant Pleural Mesothelioma
11. Xencors XmAb5871 Enters Phase 2a Study for Autoimmune Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... -- Research and Markets has announced the ... 2014" report to their offering. ... professional and in-depth study on the current state of ... provides a basic overview of the industry including definitions, ... market analysis is provided for the international markets including ...
(Date:9/18/2014)... , Sept. 18, 2014  U.S. biotech company ... an exclusive license for technology developed by the ... expression in plants, including for applications in production of ... The technology was developed under the direction of ... Kultevat and former president of the Danforth Plant Science ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... previously announced concurrent but separate underwritten offerings of 10,000,000 ... the public of $2.00 per share, for expected gross ... Series A Convertible Preferred Stock at a price to ... proceeds of $20 million. Each share of Series A ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 OMICS ... the globe to participate in the ‘Open Access ... articles to OMICS Group Pharma Journals ... one of the fastest emerging Sciences, accelerating with ... healthcare services across the globe. The industry is ...
Breaking Biology Technology:Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Kultevat obtains license of gene switch technology 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3
... Eli Lilly and Company,(NYSE: LLY ) today announced ... as a Distinguished Lilly Scholar focusing on schizophrenia,and other ... Dr. Conley join our team here at,Lilly," said Jack ... well-known thought leader, clinician and scientist who brings,important experience ...
... REINACH, Switzerland, December 14 As reported,in September, ... at this,year,s Interscience Conference on Antimicrobial Agents and ... at ICAAC, that was,supported through an educational grant ... The symposium is entitled "Treatment of Methicillin-resistant,Staphylococcus ...
... Bradley,Pharmaceuticals, Inc. (NYSE: BDY ) today announced ... the topical treatment of,external genital (EGW) and perianal ... older. Veregen(TM) is the first new,prescription treatment for ... product from MediGene AG (Frankfurt: MDG) and has ...
Cached Biology Technology:Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar 2Arpida-Supported CME Symposium Available Online 2Arpida-Supported CME Symposium Available Online 3Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 2Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 3Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 4Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 5Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 6
(Date:9/17/2014)... A UT Arlington engineering professor and his doctoral student ... that can accumulate water collected from fog and dew., ... the world or deserts around the globe., Cheng Luo, ... Xin Heng, PhD candidate in the same College of ... Aug. 25 edition of ACS, (American Chemical Society) ...
(Date:9/17/2014)... 2014) A rare genetic disorder known as Jacobsen syndrome ... joint investigation by researchers at San Diego State University ... to suggesting better treatment options for people with Jacobsen ... genetic underpinnings of autism., Jacobsen syndrome affects approximately 1 ... Health. It occurs in a person when there is ...
(Date:9/17/2014)... shopping bags and their environmental impact recently scored a ... statewide ban on the bags, and Governor Jerry Brown ... industry is not yielding without a fight, according to ... the weekly newsmagazine of the American Chemical Society. , ... the anti-bag campaign logged its first small victory in ...
Breaking Biology News(10 mins):Shorebird's beak inspires UT Arlington research on water collection 2A link between Jacobsen syndrome and autism 2
... convey vital medical information, but the sight of a needle ... developed by a team of researchers in Israel, however, can ... in real-time, simply by shining a light through the skin. ... to provide high-resolution images of blood coursing through our veins ...
... differences in bacterial colonization of the infant gut in formula-fed ... genes involved in the infant,s immune system. The study, ... access journal Genome Biology , is an Editor,s Pick. ... Texas A&M University, Miami University, and University of Arkansas scientists. ...
... of scientists from the National University of Singapore,s (NUS) Department ... drug-led compound a compound that is undergoing preclinical trials ... energy and stop them from growing into a tumour. This ... first time a research group has provided evidence showing how ...
Cached Biology News:New microscope uses rainbow of light to image the flow of individual blood cells 2New microscope uses rainbow of light to image the flow of individual blood cells 3Breast-fed babies' gut microbes contribute to healthy immune systems 2Novel discovery by NUS scientists paves the way for more effective treatment of cancers 2
... Pierce offers maleimide activated carrier proteins ... conjugates. Imject Maleimide Activated Carrier Proteins ... been preactivated with a heterobifunctional cross-linker ... stable, sulfhydryl-reactive carrier protein. Thus ...
...
... A perfect complement to high-speed analytical techniques, the AutoTrace SPE is a ... automates the cartridge conditioning, sample loading and elution steps for large volumes aqueous ... ... ...
Cell Culture Flask, 25 cm, tissue-culture treated polystyrene...
Biology Products: